immune modulation comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-10-04. Numbers and descriptions here follow the published literature rather than marketing material.
The compound has been investigated as an adjunct in chronic viral hepatitis and as a vaccine adjuvant, with results that vary by study design and population. Regulators in some countries have approved a synthetic form for specific indications, while other agencies have not. Whether the peptide produces consistent clinical benefit across diverse patient groups is still an open question, and many trials have been small. Its status is therefore best described as investigational in many contexts and established only narrowly.
The name itself causes confusion, because several unrelated thymic peptides share the thymosin label. Thymosin beta-4, for example, is a different molecule with different functions. Naming conventions in the literature also mix descriptive research terms with assigned nonproprietary names, so a reader should confirm which entity a given paper addresses. Clarifying that point is usually the first step in interpreting any claim about this peptide.
Thymosin alpha-1 is a short peptide of 28 amino acid residues first described in the 1970s as a component of thymic extracts. Its N-terminal residue carries an acetyl group, and the sequence is highly conserved across mammalian species. The peptide is not encoded as a standalone gene product; it is released by proteolytic cleavage from the N-terminus of prothymosin alpha, a larger acidic nuclear protein. That precursor relationship places it within a broader family of thymic and immune-associated peptides that have been studied for decades.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
| Property | Value | Notes |
|---|---|---|
| Residue count | 28 amino acids | Acetyl group on the first residue |
| Approximate molecular mass | 3108 daltons | Calculated from the consensus sequence |
| Origin | Cleavage product of prothymosin alpha | Not encoded as a separate gene product |
| Primary research focus | Immune modulation | Studied in viral hepatitis and as a vaccine adjuvant |
| Common synonyms | Thymalfasin, Tα1, thymosin alpha 1 | Thymalfasin is the assigned nonproprietary name |
Thymosin alpha-1 is supplied as a lyophilized powder in most research settings. The solid dissolves readily in water and in common aqueous buffers, and it is typically reconstituted shortly before use. Solutions are clear and colourless at ordinary working concentrations. Because the peptide is hygroscopic, weighing and reconstitution are usually performed with minimal exposure to ambient air. Aliquots are prepared to avoid repeated freeze-thaw cycles, and working solutions are kept cold.
Long-term storage is generally at minus twenty degrees Celsius or colder, preferably desiccated and protected from light. Lyophilized material is more stable than reconstituted solution, which degrades faster at room temperature. Stability depends on pH, ionic strength, and the presence of oxidising agents. Published stability data for the peptide are limited, so storage claims in catalogues should be treated as general guidance rather than measured guarantees. Freeze-thaw cycles are kept to a minimum.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Storage recommendations center on low temperature, dryness, and protection from repeated freezing and thawing. The intact powder is commonly held at 20 degrees below zero Celsius or colder, while a working solution is divided into single-use aliquots to limit freeze-thaw cycles. Buffered saline or phosphate-buffered saline at neutral pH is frequently used as a diluent. Light sensitivity is not well documented, yet amber vials or foil wrapping are common practice for long-term storage of peptide stocks.
Identity and purity are assessed with a small set of standard peptide methods. Reversed-phase high-performance liquid chromatography separates the main peak from truncated or oxidized species, and its area percentage is the usual purity measure. Mass spectrometry confirms the observed molecular mass against the expected value, while amino acid analysis or peptide mapping checks composition and sequence. Specifications for research-grade material are often stated as 95 percent or higher, though the exact limit depends on the supplier and the intended use.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
=== Hypoglycemia === Hypoglycemia, or abnormally low blood glucose, is an acute complication of several diabetes treatments. It is rare otherwise, either in diabetic or non-diabetic patients. The patient may become agitated, sweaty, weak, and have many symptoms of sympathetic activation of the autonomic nervous system resulting in feelings akin to dread and immobilized panic. Consciousness can be altered or even lost in extreme cases, leading to coma, seizures, or even brain damage and death. In patients with diabetes, this may be caused by several factors, such as too much or incorrectly timed insulin, too much or incorrectly timed exercise (exercise decreases insulin requirements) or not enough food (specifically glucose containing carbohydrates). The variety of interactions makes cause identification difficult in many instances. It is more accurate to note that iatrogenic hypoglycemia is typically the result of the interplay of absolute (or relative) insulin excess and compromised glucose counterregulation in type 1 and advanced type 2 diabetes. Decrements in insulin, increments in glucagon, and, absent the latter, increments in epinephrine are the primary glucose counterregulatory factors that normally prevent or (more or less rapidly) correct hypoglycemia. In insulin-deficient diabetes (exogenous) insulin levels do not decrease as glucose levels fall, and the combination of deficient glucagon and epinephrine responses causes defective glucose counterregulation. Furthermore, reduced sympathoadrenal responses can cause hypoglycemia unawareness.
Their southernmost settlements being around Schwansen, Hedeby and Husum, mirroring the same southern border as their Angle predecessors. As raiding was a frequent practice among the Danes, Saxons, and Wagrians, the borderlands was a hostile and unsafe area to inhabit. In response to these threats, the Danes began constructing the Danevirke. Originally built as a dyke, it was gradually expanded into a 30-kilometer earthwork with a palisade fortification, forming a barrier between the Danes and their southern neighbors. The Danevirke was strategically positioned at the narrowest point of the peninsula, with its eastern end beginning at the Treene River and extending to the Schlei Bay. This fortification served to deter Saxon and Wagrian raids while enabling the Danes to launch their own raids into southern territories. It would remain in use until 1864, being expanded and adapted to the changing military needs of the Danes multiple times. The establishment of the Danevirke not only helped to prevent Saxon and Wagrian raids into Danish territory but also served as a toll station. Danish chieftains would collect fees from traders, merchants, and peasants traveling along the Hærvejen (Heerweg/Armyway), the main trade route running through the peninsula. Saxons, Wagrians, and Danes alike used the Hærvejen to trade goods such as honey, furs, amber, glass, metalwork, and other commodities, such as livestock, with cattle and oxen being particularly important.
== Structure and properties == The chemical name N5-ethyl-L-glutamine and other synonyms (see box) for theanine reflect its chemical structure. The name theanine, without prefix, is generally understood to imply the L- (S-) enantiomer, derived from the related proteinogenic L-amino acid glutamic acid. Theanine is an analog of this amino acid, and its primary amide, L-glutamine (also a proteinogenic amino acid). Theanine is a derivative of glutamine that is ethylated on the amide nitrogen (as the name N5-ethyl-L-glutamine describes), or alternatively, to the amide formed from ethylamine and L-glutamic acid at its γ- (5-) side chain carboxylic acid group (as the name γ-L-glutamylethylamide describes). Relative to theanine, the opposite (D-, R-) enantiomer is largely absent from the literature, except implicitly. While natural extracts that are not harshly treated are presumed to contain only the biosynthetic L- enantiomeric form, mishandled isolates and racemic chemical preparations of theanines necessarily contain both theanine and its D-enantiomer (and from racemic syntheses, in equal proportion), and studies have suggested that the D-isomer may actually predominate in some commercial supplement preparations.
Cases of intentional suicide by overdose using etizolam in combination with GABA agonists have been reported. Etizolam has a lower LD50 than certain benzodiazepines. Flumazenil, a GABA antagonist agent used to reverse benzodiazepine overdoses, inhibits the effect of etizolam as well as classical benzodiazepines such as diazepam and chlordiazepoxide. Etizolam overdose deaths are rising in Scotland, especially among women - for instance, the National Records of Scotland report on drug-related deaths have, "have increased significantly in Scotland in recent years, with a much greater percentage increase in deaths among women than among men". By 2018, 1,187 overdoses were officially recorded, a 107% increase from 2008, this means that this has been the highest peak to date. Although, men still outnumber women in drug-related deaths.
Sources: en.wikipedia.org
Through this mechanism the liver may be restored to its original state, scar-free. However, despite nearly 80 years of research on liver regeneration much debate still surrounds the exact mechanisms by which the process occurs. Another example of spontaneous regeneration endometrial lining of the uterus after menses during reproductive years. Endometrial glands from a basal layer of the uterine wall can regenerate the functional layer without fibrosis or scarring. By 2014 the kidney had been found to have the ability to regenerate. Following removal or incapacitation of one kidney the other may double in size in order to counteract the loss of the other kidney. This is known a compensatory growth. Induced regeneration stimulated by an outside source of a "non-regenerative" organ. In humans is for therapeutic use. Induced regeneration is being trialled to replace organ transplants as issues such as rejection, lack of donors, and scarring would be eliminated. The table below details some of the tissues in which induced regeneration has been attempted;
The side effects of elagolix are in general similar to menopausal symptoms. The most common side effects of elagolix (incidence ≥10%) are hot flashes, night sweats, headaches, nausea, and amenorrhea (cessation of menstruation). The next most frequent side effects of elagolix (incidence ≥5%) are insomnia, anxiety, arthralgia (joint pain), depression, and mood changes. Less common side effects of elagolix (incidence ≥3% and <5%) include decreased sex drive, diarrhea, abdominal pain, weight gain, dizziness, constipation, and irritability. Other common side effects of elagolix include decreased bone mineral density (BMD) and changes in the blood lipid profile. Rare but serious adverse effects that were observed during elagolix therapy in clinical trials included appendicitis (0.3%), abdominal pain (0.2%), and back pain (0.2%), though it is unknown if these were due to elagolix. Other serious adverse effects of elagolix may include bone loss, miscarriage, suicidality, and elevated liver enzymes. Elagolix was discontinued due to side effects by 5 to 10% of women in clinical trials, with the most common reasons being hot flashes or night sweats, nausea, and decreased BMD. Elagolix dose- and duration-dependently decreases BMD in premenopausal women with long-term therapy. After 6 months of treatment with elagolix, lumbar spine BMD was decreased by 0.3 to 1.3% with 150 mg once per day and by 2.5 to 3.1% with 200 mg twice per day.
Honey collection is an ancient activity, long preceding the honey bee's domestication; this traditional practice is known as honey hunting. A Mesolithic rock painting in a cave in Valencia, Spain, dating back at least 8,000 years, depicts two honey foragers collecting honey and honeycomb from a wild bees' nest. The figures are depicted carrying baskets or gourds, and using a ladder or series of ropes to reach the nest. Humans followed the greater honeyguide bird to wild beehives; this behavior may have evolved with early hominids. The oldest known honey remains were found in Georgia during the construction of the Baku–Tbilisi–Ceyhan pipeline: archaeologists found honey remains on the inner surface of clay vessels unearthed in an ancient tomb, dating back between 4,700 and 5,500 years. In ancient Georgia, several types of honey were buried with a person for journeys into the afterlife, including linden, berry, and meadow-flower varieties. The first written records of beekeeping are from ancient Egypt, where honey was used to sweeten cakes, biscuits, and other foods and as a base for unguents in Egyptian hieroglyphs. The dead were often buried in or with honey in Egypt, Mesopotamia and other regions. Bees were kept at temples to produce honey for temple offerings, mummification and other uses. In southern Illyria (present day Albania), the Iron Age Illyrian tribe of the Abroi were known for preparing mead, a wine from honey, as documented by Hecataeus of Miletus in the 6th century BCE. In ancient Greece, honey was produced from the Archaic to the Hellenistic periods.
Sources: en.wikipedia.org
It is usually classified as an immunomodulatory peptide rather than a classical hormone. It derives from the larger protein prothymosin alpha and acts mainly on immune cells. The thymosin label covers a group of distinct peptides, so the naming can be misleading.
The two share a family name but have different sequences, sizes, and functions. Thymosin beta-4 is a 43-residue peptide associated with actin binding and cell migration. Thymosin alpha-1 is a 28-residue peptide linked mainly to immune signaling.
Thymalfasin is the assigned international nonproprietary name for the synthetic 28-residue peptide. Thymosin alpha-1 is the descriptive research name for the same molecule. Which term appears depends on the context and the regulatory document.
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.